Volume 19, Number 2—February 2013
Dispatch
Macrolide- and Rifampin-Resistant Rhodococcus equi on a Horse Breeding Farm, Kentucky, USA
Table 2
Foal ID no. | Pretreatment isolates (cluster) | % Similarity† | Posttreatment isolates (cluster) |
---|---|---|---|
7-11 | S | 97.5 | S |
5-11 | S | 84.3 | S |
14-11 | R (E) | 96.4 | R (E) |
3-11 | R (B) | 96.5 | R (B) |
4-11 | R (B) | 97.4 | R (B) |
17-11 | R (C) | 98.5 | R (C) |
20-11 | S | 83.1 | R (B) |
18-11 | S | 78 | R (C) |
11-11 | R (B) | 87.2 | S |
15-11‡ | S | 83.1 | S |
NA | 73.2 | R (D) | |
16-11‡ | S | 78.8 | R (D) |
R (B) | 80.8 | NA |
*ID, identification; S, susceptible; R, resistant; NA, not applicable.
†Determined by using Pearson correlation coefficient and unweighted pair-group method with arithmetic means.
‡Two isolates were recovered from the pretreatment (foal ID 16-11) or posttreatment (foal ID 15-11) sampling.
1Current affiliation: Kalon Biotherapeutics LLC, College Station, Texas, USA.
Page created: January 22, 2013
Page updated: January 22, 2013
Page reviewed: January 22, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.